Studies venetoclax with azacitidine in adults newly diagnosed with acute myeloid leukemia
Observes how venetoclax with azacitidine is used for acute myeloid leukemia in adults.
Plain-language title generated from the registry record
Registry title: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
Key facts
- Where
- Bogota, Bogota DC, Cali, Floridablanca, Medellin, Medellín, and Valledupar, ColombiaSee the 8 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemotherapy and are starting venetoclax with azacitidine in Colombia.
- Age
- 18 years or older. People aged 75 or older, or aged 18 to 74 with other health problems that rule out intensive chemotherapy.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed AML (de novo or secondary), confirmed by tissue examination using World Health Organization (WHO) criteria.
- Earlier treatment
- No earlier treatment for AML. Starting venetoclax with azacytidine as set out in the Colombia label, and the first 28-day cycle not yet completed.
Main reasons for not taking part
- Took part in an interventional clinical trial within 30 days before starting venetoclax
Read by machine on 12 November 2026.
Where in Colombia
- Clinica del Country /ID# 248430Bogota, ColombiaContact: Angela DuarteTaking people
- Fundacion Santa Fe De Bogota /ID# 248563Bogota, ColombiaContact: Angela DuarteTaking people
- Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 248570Bogota DC, ColombiaContact: Angela DuarteNo longer taking part
- Fundacion Valle Del Lili /ID# 248294Cali, ColombiaContact: Angela DuarteNo longer taking part
- FOSCAL International /ID# 287252Floridablanca, ColombiaContact: Angela DuarteNo longer taking part
- Hospital Alma Mater de Antioquia /ID# 248562Medellin, ColombiaContact: Angela DuarteNo longer taking part
- Hospital Pablo Tobon Uribe /ID# 248569Medellín, ColombiaContact: Angela DuarteNo longer taking part
- Sociedad de Oncologia y Hematologia del Cesar /ID# 248615Valledupar, ColombiaContact: Angela DuarteNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT05587049
- Record updated
- 26 August 2026
- Original description
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia.Read full original descriptionShow less
Effectiveness and Safety of Venetoclax in Combination With Azacitidine in Patients With Acute Myeloid Leukemia in Real Life Clinical Practice
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia.
Venetoclax in combination with azacytidine is approved to treat Acute myeloid leukemia (AML). All study participants will receive venetoclax in combination with azacitidine as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML will be enrolled. Around 70 participants will be enrolled in the study in Colombia.
Participants will receive venetoclax tablets to be taken by mouth in combination with azacitidine given by subcutaneous (SC) or intravenous (IV) injection according to the approved local label. The duration of the study is approximately 36 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.
Inclusion: Newly diagnosed acute myeloid leukemia (AML) defined as participants that have histological confirmation of AML (de novo, secondary) by World Health Organization (WHO) criteria, and have not received any prior treatment for AML; Ineligible to intensive chemotherapy due to >=75 years of age; or >=18 to 74 years who have comorbidities that preclude use of intensive induction chemotherapy; Participants starting treatment with venetoclax in combination with azacytidine treated according to the Colombia label and who are not completed the first cycle (Cycle 28 days).
Exclusion: Participating in an interventional clinical trial within 30 days prior to Venetoclax treatment initiation.